Fresenius launches Actemra biosimilar in USA

16 April 2024
fresenius_kabi_large

Germany’s Fresenius (ETR: FRE) - via its operating company Fresenius Kabi - has announced the immediate US availability of Tyenne (tocilizumab-aazg), a biosimilar of Roche’s (ROG: SIX) Actemra (tocilizumab).

Tyenne, for use in the treatment of chronic autoimmune diseases, is available in an intravenous (IV) formulation.

Reference drug Actemra earned more than 1.2 billion Swiss francs ($1.39 billion) in sales in the USA in 2023, and 2.6 billion francs globally.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars